Advanced Chinese Medicine最新文献

{"title":"The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta-analyses","authors":"JingYi Zhao,&nbsp;Min Li,&nbsp;KaiLe Ma,&nbsp;Rui Hao,&nbsp;LiJuan Zhou","doi":"10.1002/acm4.3","DOIUrl":"10.1002/acm4.3","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], <i>p</i> &lt; 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], <i>p</i> &lt; 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], <i>p</i> = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], <i>p</i> = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], <i>p</i> = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], <i>p</i> &lt; 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], <i>p</i> = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], <i>p</i> = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], <i>p</i> = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], <i>p</i> = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"66-78"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139802928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta‐analyses","authors":"J. Zhao, Min Li, Kaile Ma, Rui Hao, Lijuan Zhou","doi":"10.1002/acm4.3","DOIUrl":"https://doi.org/10.1002/acm4.3","url":null,"abstract":"This meta‐analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk‐of‐bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], p < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], p < 0.00001). Waist‐to‐hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], p = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], p = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], p = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], p < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], p = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], p = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], p = 0.003), and low‐density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], p = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity‐related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"187 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To explore the pathogenesis and scientific connotation of non-alcoholic fatty liver based on the theory of turbid toxin of traditional Chinese medicine","authors":"Guanjun Kou,&nbsp;Hongwei Luo,&nbsp;Xing Huang,&nbsp;Mingxue Bai,&nbsp;Ke Cao,&nbsp;Hongyu Ma,&nbsp;Xiang Lv","doi":"10.1002/acm4.1","DOIUrl":"10.1002/acm4.1","url":null,"abstract":"<p>Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease characterized by the accumulation of excessive liver lipids without alcohol-induced damage. It has emerged as a significant global health issue. A recent research has indicated that dysregulation of lipid decomposition, uptake, production, oxidation, and secretion causes alterations in various types of lipids, leading to organelle dysfunction and metabolic signaling pathway impairment. Scholars propose that turbid toxin is crucial in the pathogenesis of NAFLD. This article elucidates the meaning of turbid toxin in conjunction with the current literature and analyzes the modern pathophysiological mechanism underlying the development of NAFLD, including turbid toxic substance production, related organelle involvement, biological processes, and pathways, ultimately leading to disease outcomes. The relationship between traditional Chinese medicine and the turbid toxin is also explored to establish a foundation for further mechanistic research on NAFLD.</p>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"40-51"},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139445351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}